Kiniksa Pharmaceuticals (NASDAQ:KNSA) Releases Earnings Results, Beats Expectations By $0.03 EPS

Kiniksa Pharmaceuticals (NASDAQ:KNSA) announced its earnings results on Tuesday. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03, Briefing.com reports. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.83%. The firm had revenue of $108.30 million for the quarter, compared to analyst estimates of $90.60 million. During the same quarter in the previous year, the firm posted ($0.02) EPS. The company’s revenue for the quarter was up 51.5% compared to the same quarter last year.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA traded up $0.21 during mid-day trading on Friday, hitting $26.12. 372,983 shares of the company traded hands, compared to its average volume of 428,985. Kiniksa Pharmaceuticals has a 1 year low of $14.12 and a 1 year high of $27.88. The stock has a 50-day moving average price of $19.84 and a two-hundred day moving average price of $19.42. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of 235.57 and a beta of 0.38.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Evercore ISI boosted their price objective on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Wells Fargo & Company began coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, May 3rd. They set an “overweight” rating and a $34.00 price objective on the stock. Wedbush upped their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. upped their target price on shares of Kiniksa Pharmaceuticals from $26.00 to $30.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Four investment analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $32.00.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, CEO Sanj K. Patel sold 136,124 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $25.65, for a total transaction of $3,491,580.60. Following the completion of the sale, the chief executive officer now directly owns 63,012 shares in the company, valued at approximately $1,616,257.80. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Kiniksa Pharmaceuticals news, CEO Sanj K. Patel sold 136,124 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $25.65, for a total transaction of $3,491,580.60. Following the completion of the sale, the chief executive officer now directly owns 63,012 shares in the company, valued at approximately $1,616,257.80. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider John F. Paolini sold 22,000 shares of the company’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $26.32, for a total transaction of $579,040.00. Following the sale, the insider now directly owns 47,803 shares of the company’s stock, valued at approximately $1,258,174.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 182,372 shares of company stock worth $4,671,729. 54.57% of the stock is owned by insiders.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.